A randomized trial of icosapent ethyl in ambulatory patients with COVID-19

被引：20

作者：

Kosmopoulos, Andrew ^{[1
,2
,3
]}

Bhatt, Deepak L. ^{[4
]}

Meglis, Gus ^{[1
]}

Verma, Raj ^{[1
]}

Pan, Yi ^{[2
]}

Quan, Adrian ^{[2
]}

Teoh, Hwee ^{[2
,5
]}

Verma, Maya ^{[1
]}

Jiao, Lixia ^{[6
]}

Wang, Robert ^{[6
]}

Juliano, Rebecca A. ^{[6
]}

Kajil, Mahesh ^{[1
]}

Kosiborod, Mikhail N. ^{[7
,8
,9
,10
]}

Bari, Basel ^{[11
]}

Berih, Abdullahi A. ^{[12
]}

Aguilar, Mallory ^{[1
]}

Escano, Antonnette ^{[1
]}

Leung, Andrew ^{[13
]}

Coelho, Idelta ^{[13
]}

Hibino, Makoto ^{[2
]}

Diaz, Rafael ^{[14
]}

Mason, R. Preston ^{[15
]}

Steg, Ph Gabriel ^{[16
,17
,18
]}

Simon, Tabassome ^{[17
,19
]}

Go, Alan S. ^{[20
,21
,22
]}

Ambrosy, Andrew P. ^{[20
,23
]}

Choi, Richard ^{[24
,25
]}

Kushner, Arthur M. ^{[26
]}

Leiter, Lawrence A. ^{[5
,27
,28
]}

Al-Omran, Mohammed ^{[29
,30
]}

Verma, Subodh ^{[1
,2
,3
,30
,31
]}

Mazer, C. David ^{[32
,33
,34
]}

机构：

[1] North York Diagnost & Cardiac Ctr, Toronto, ON, Canada

[2] St Michaels Hosp, Unity Hlth Toronto, Li Ka Shing Knowledge Inst, Div Cardiac Surg, Toronto, ON, Canada

[3] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada

[4] Brigham & Womens Hosp, Harvard Med Sch, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA

[5] St Michaels Hosp, Unity Hlth Toronto, Li Ka Shing Knowledge Inst, Div Endocrinol & Metab, Toronto, ON, Canada

[6] Amarin Pharma Inc, Bridgewater, NJ USA

[7] St Lukes Mid Amer Heart Inst, Dept Cardiol, Kansas City, MO USA

[8] Univ Missouri Kansas City, Dept Med, Kansas City, MO USA

[9] George Inst Global Hlth, Sydney, NSW, Australia

[10] Univ New South Wales, Sydney, NSW, Australia

[11] Markham Hlth Plex Med Ctr, Markham, ON, Canada

[12] Humber Ctr Family Hlth, Etobicoke, ON, Canada

[13] Alpha Labs Inc, Toronto, ON, Canada

[14] Inst Cardiovasc Rosario, Estudios Clin Latino Amer, Rosario, Argentina

[15] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, Boston, MA 02115 USA

[16] Univ Paris, AP HP, INSERM 1148, Paris, France

[17] French Alliance Cardiovasc Trials FACT, Paris, France

[18] Imperial Coll, Royal Brompton Hosp, Natl Heart & Lung Inst NHLI, London, England

[19] Sorbonne Univ, Hop St Antoine, AP HP,Site St Antoine, Dept Clin Pharmacol,Unite Rech Clin URCEST,INSERM, Paris, France

[20] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA

[21] Univ Calif San Francisco, Dept Epidemiol Biostat & Med, San Francisco, CA 94143 USA

[22] Stanford Univ, Dept Med, Sch Med, Div Nephrol, Stanford, CA 94305 USA

[23] Kaiser Permanente San Francisco Med Ctr, Div Cardiol, San Francisco, CA USA

[24] St Josephs Hlth Ctr, Unity Hlth Toronto, Riverside Cardiol & Diagnost Imaging, Toronto, ON, Canada

[25] St Josephs Hlth Ctr, Unity Hlth Toronto, Div Cardiol, Toronto, ON, Canada

[26] Humber River Hosp, Toronto, ON, Canada

[27] Univ Toronto, Dept Med, Toronto, ON, Canada

[28] Univ Toronto, Dept Nutr Sci, Toronto, ON, Canada

[29] St Michaels Hosp, Unity Hlth Toronto, Li Ka Shing Knowledge Inst, Div Vasc Surg, Toronto, ON, Canada

[30] Univ Toronto, Dept Surg, Toronto, ON, Canada

[31] Canadian Med & Surg Knowledge Translat Res Grp, Toronto, ON, Canada

[32] St Michaels Hosp, Unity Hlth Toronto, Li Ka Shing Knowledge Inst, Dept Anesthesia, Toronto, ON, Canada

[33] Univ Toronto, Dept Anesthesiol & Pain Med, Toronto, ON, Canada

[34] Univ Toronto, Dept Physiol, Toronto, ON, Canada

来源：

ISCIENCE | 2021年 / 24卷 / 09期

关键词：

Health sciences; Medicine;

D O I：

10.1016/j.isci.2021.103040

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The coronavirus disease 2019 (COVID-19) pandemic remains a source of considerable morbidity and mortality throughout the world. Therapeutic options to reduce symptoms, inflammatory response, or disease progression are limited. This randomized open-label trial enrolled 100 ambulatory patients with symptomatic COVID-19 in Toronto, Canada. Results indicate that icosapent ethyl (8 g daily for 3 days followed by 4 g daily for 11 days) significantly reduced high-sensitivity C-reactive protein (hs-CRP) and improved symptomatology compared with patients assigned to usual care. Specifically, the primary biomarker endpoint, change in hs- CRP, was significantly reduced by 25% among treated patients (-0.5 mg/L, interquartile range [IQR] [-6.9,0.4], withingroup p = 0.011). Conversely, a non-significant 5.6% reduction was observed among usual care patients (-0.1 mg/L, IQR [-3.2,1.7], within-group p = 0.51). An unadjusted between-group primary biomarker analysis was non-significant (p = 0.082). Overall, this report provides evidence of an early anti-inflammatory effect of icosapent ethyl in a modest sample, including an initial well-tolerated loading dose, in symptomatic outpatients with COVID-19.

引用

页数：11

共 21 条

[1] A Revolution in Omega-3 Fatty Acid Research [J].

Bhatt, Deepak L. ;

Budoff, Matthew J. ;

Mason, R. Preston .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (18) :2098-2101

[2] Beyond cardiovascular medicine: potential future uses of icosapent ethyl [J].

Bhatt, Deepak L. ;

Hull, Mark A. ;

Song, Mingyang ;

Van Hulle, Carol ;

Carlsson, Cindy ;

Chapman, M. John ;

Toth, Peter P. .

EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0J) :J54-J64

[3] Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia [J].

Bhatt, Deepak L. ;

Steg, P. Gabriel ;

Miller, Michael ;

Brinton, Eliot A. ;

Jacobson, Terry A. ;

Ketchum, Steven B. ;

Doyle, Ralph T., Jr. ;

Juliano, Rebecca A. ;

Jiao, Lixia ;

Granowitz, Craig ;

Tardif, Jean-Claude ;

Ballantyne, Christie M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) :11-22

[4] Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial [J].

Budoff, Matthew J. ;

Bhatt, Deepak L. ;

Kinninger, April ;

Lakshmanan, Suvasini ;

Muhlestein, Joseph B. ;

Le, Viet T. ;

May, Heidi T. ;

Shaikh, Kashif ;

Shekar, Chandana ;

Roy, Sion K. ;

Tayek, John ;

Nelson, John R. .

EUROPEAN HEART JOURNAL, 2020, 41 (40) :3925-3932

[5] The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial [J].

Doaei, Saeid ;

Gholami, Somayeh ;

Rastgoo, Samira ;

Gholamalizadeh, Maryam ;

Bourbour, Fatemeh ;

Bagheri, Seyedeh Elaheh ;

Samipoor, Forough ;

Akbari, Mohammad Esmail ;

Shadnoush, Mahdi ;

Ghorat, Fereshteh ;

Mosavi Jarrahi, Seyed Alireza ;

Ashouri Mirsadeghi, Narjes ;

Hajipour, Azadeh ;

Joola, Parvin ;

Moslem, Alireza ;

Goodarzi, Mark O. .

JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)

[6] Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model [J].

Han, Alison ;

Poon, Jiat-Ling ;

Powers, John H., III ;

Leidy, Nancy K. ;

Yu, Ren ;

Memoli, Matthew J. .

BMC INFECTIOUS DISEASES, 2018, 18

[7]

Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]

[8] Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation [J].

Lamon-Fava, Stefania ;

So, Jisun ;

Mischoulon, David ;

Ziegler, Thomas R. ;

Dunlop, Boadie W. ;

Kinkead, Becky ;

Schettler, Pamela J. ;

Nierenberg, Andrew A. ;

Felger, Jennifer C. ;

Maddipati, Krishna Rao ;

Fava, Maurizio ;

Rapaport, Mark Hyman .

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2021, 164

[9] Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid [J].

Mason, R. Preston ;

Libby, Peter ;

Bhatt, Deepak L. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2020, 40 (05) :1135-1147

[10] New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease [J].

Mason, R. Preston .

CURRENT ATHEROSCLEROSIS REPORTS, 2019, 21 (01)

← 1 2 3 →